Anticipating Drug Toxicity: data-driven drug safety with DISGENET plus
August 18, 2023 | Laura I. Furlong Key points Flupirtine, an aminopyridine introduced in 1984 as a non-opioid analgesic for acute and chronic pain, embarked on a tumultuous journey within the medical landscape. Initially approved for broad pain management, its trajectory shifted in 2013 due to concerns over liver toxicity. The European Medicines Agency (EMA) […]
Read More
Genetics for drug and chemical risk assessment
Genetics for drug and chemical risk assessment In recent years, there has been an increasing appreciation of the need to consider variability in human populations in evaluating health risks for new and existing chemicals. Recent policies such as The Frank R. Lautenberg Chemical Safety for the twenty-first Century Act (2016) require the US Environmental Protection […]
Read More
Genetic support for FDA approvals in 2021
Genetic support for FDA approvals in 2021 Key points Human genetics and FDA drug approvals in 2021 There is compelling evidence of the value of incorporating genetic information in the drug development process. A drug target supported by genetic evidence has a 2-fold higher probability of successful clinical development compared to those targets with no […]
Read More
The importance of genomic findings to help diagnose and treat rare diseases.
The importance of genomic findings to help diagnose and treat rare diseases. In Europe it is estimated that up to 36 million people live with a rare disease. More than 6,000 rare diseases have been identified in the EU. Some might just impact a few patients but others are calculated to affect at most 245,000 […]
Read More